Stem cell therapy in fertility: the regenerative medicine frontier, read responsibly

Stem cell therapy in fertility is one of the most actively-researched and most over-promoted areas in reproductive medicine. There is real signal in early data. There is also a lot of noise, marketing, and clinics charging substantial fees for treatments that do not yet have rigorous evidence behind them. Reading the field responsibly matters.

What is being studied, and why

Three main directions in fertility regenerative medicine: ovarian rejuvenation using platelet-rich plasma (PRP) or autologous stem cell injection in patients with diminished ovarian reserve or premature ovarian insufficiency; endometrial regeneration using PRP or stem cells in patients with thin endometrium or Asherman syndrome; and testicular regeneration in azoospermia, primarily a research domain.

What the evidence currently supports

For thin endometrium and Asherman syndrome, intrauterine PRP has the strongest published support. Several small randomised trials show meaningful improvement in lining thickness and pregnancy rates, particularly in patients who have failed standard hormonal preparation. PRP is autologous (made from the patient’s own blood), low-risk, and increasingly available at registered clinics.

For ovarian rejuvenation, the data is much earlier. Some case series report improvements in AMH, antral follicle count, and pregnancy rates after intra-ovarian PRP. Randomised trials are ongoing but small. Major fertility societies have so far stopped short of routine recommendation outside research settings.

What is currently overstated

Claims of “ovarian reversal” in postmenopausal women, “guaranteed” results from PRP cycles, or stem cell therapies offered for routine IVF augmentation in patients with normal reserve. The marketing around regenerative medicine often runs ahead of the data. A clinic offering stem cell therapy for any indication should be able to point to specific peer-reviewed evidence in patients like you, not generic enthusiasm.

How to read a recommendation

Ask the specific indication, the specific intervention (PRP, autologous stem cells, allogeneic, what kind), the published evidence base for that combination, and the expected effect size. If a clinic cannot answer those questions clearly, the offer is more marketing than medicine.

Questions worth asking your doctor

• What specifically is being injected, where, and why for me?
• Is this PRP from my own blood, or stem cells from another source?
• What published evidence supports this intervention for a patient like me?
• What is the realistic effect size on my outcomes, and what is the cost?
• Is this part of a registered research protocol, or standard care, or something in between?

This essay is educational. Every patient’s situation is different – the right plan is shaped in conversation with a fertility specialist who knows the full picture.